Cigna's Strategic Push Towards Specialty Care
Cashu Finance·5 min read

TL;DR
- Cigna targets $45 EPS by 2030, focusing on specialty care.
- Challenges in pharmacy benefit services are expected due to regulatory impacts.
- Commitment to community health through mental health support initiatives.
Cigna Corporation (CI) is on the precipice of a significant transformation as it refocuses its business strategy with an ambitious target for the future. With the healthcare industry undergoing rapid changes, Cigna’s stockholders are looking closely at how the company plans to navigate these complexities while maximizing growth and profitability. The latest outlines from company executives indicate a shift towards specialty care services, which are expected to be pivotal for Cigna’s revenue growth moving forward.
Targeting Specialty Care for Long-Term Growth
Cigna is setting a favorable forecast with expectations to drive earnings upwards, ultimately targeting at least $45 per share by 2030. This ambition, articulated by Chief Financial Officer Ann Dennison at a recent industry conference, emphasizes that the specialty business is predicted to evolve and account for a larger share of Cigna's overall earnings, potentially increasing from 37% to 40% by 2030.
Essentially, Cigna's specialty segment has been identified as the fastest-growing domain within the company's portfolio, projected to grow between 8% and 12%. This division not only bolsters earnings potential but also strategically positions Cigna to meet shifting consumer demands for specialized healthcare solutions.
Navigating Pharmacy Headwinds
However, Cigna acknowledges it faces headwinds within its pharmacy benefit services, primarily driven by changes in employer coverage for certain drug treatments and a diminishing rebate pool. Notably, the Inflation Reduction Act (IRA) is expected to exert pressure on Cigna’s revenue, resulting in lower earnings from rebates. This is crucial for investors to consider, as it reflects a potential hurdle for revenue stability in its current pharmacy segment.
Despite these challenges, Cigna remains optimistic about returning to growth in pharmacy services post-2027, with the introduction of its innovative Signature pharmacy benefit model. This model, set to launch in early 2027, is designed to enhance transparency in pricing for employers, fostering a more predictable financial environment for the company and its clients.

